Recruiting PHASE3 INTERVENTIONAL 4-arm NCT05621070

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Conditions Primary Hypercholesterolaemia and Mixed Dyslipidemia

Interventions JS002 Placebo

Updated 4 times since 2022 Last updated: Sep 9, 2024 Started: Feb 3, 2023 Primary completion: Sep 23, 2024 Completion: Sep 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Primary Hypercholesterolaemia and Mixed Dyslipidemia and is currently actively recruiting participants. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Oct 2024 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Dec 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Junshi Bioscience Co., Ltd.

Data source: Shanghai Junshi Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China